Ursodeoxycholic acid (UDCA) is a potent inhibitor of liver-specific fatty acid transporter 5 (FATP5). Ursodeoxycholic acid inhibits cholesterol absorption and is used to dissolve gallstones.

GBM:> 50 μM, CHO cells:36.4 μM (EC50), A549 cells:> 200 μM

METHODS: Ovarian cancer cell line A2780 and cisplatin-resistant cell line A2780 were treated with Ursodeoxycholic acid (300 nM) for 4 hours, and the cell growth inhibition was detected by MTT assay.
RESULTS: Ursodeoxycholic acid inhibited the growth of ovarian cancer A2780 cells (IC50=300 nM) and cisplatin-resistant A2780 cells (IC50=300 nM). [1]
METHODS: Colorectal cancer cells SW620 and HCT116 were treated with Ursodeoxycholic acid (0, 0.00625, 0.0125, 0.025, 0.05, 0.1 mg/mL) for 24 hours, and MTT assay was used to detect the inhibitory effect of ursodeoxycholic acid on cell growth.
RESULTS: Ursodeoxycholic acid inhibited the growth of colorectal cancer cells SW620 (IC50=0.02 mg/mL) and HCT116 (IC50=0.016 mg/mL). [2]

METHODS: To study the effect of Ursodeoxycholic acid on body weight, Ursodeoxycholic acid (50, 150, and 450 mg/kg) was administered orally to mice for 21 days.
RESULTS: Significant weight loss was observed within a week in the groups of mice receiving 50 and 450 mg/kg doses. At the 50 mg/kg dose, this weight loss persisted throughout the experiment. At a dose of 450 mg/kg, weight loss was initially observed during the first and third weeks of Ursodeoxycholic acid administration. At the 150 mg/kg dose, there was no significant difference in body weight compared to untreated mice. [3]